To evaluate whether trabectedin as first-line chemotherapy for advanced/metastatic soft tissue sarcoma prolongs progression-free survival ( PFS ) , compared to doxorubicin and , in the phase IIb part here , to select the most appropriate trabectedin treatment schedule ( 3-hour or 24-hour infusion ) in terms of safety , convenience and efficacy .